Procurement of chemical reagents

Jiangsu Aikon Biomedical, trustworthy. Focused on R&D, dedicated service. Jiangsu Aikon Biomedical Co., Ltd. was established in 2014 and is located in the beautiful city of Nanjing, Jiangsu. Relying on advanced domestic and international technical expertise and expert resources, Jiangsu Aikon Biomedical has established close cooperative relationships with numerous enterprises both at home and abroad. It is a large-scale, high-quality procurement service provider for laboratory reagents and biological reagents in China.

Pharmaceutical intermediates include both general and custom products. Depending on the stage of outsourcing services, the custom intermediate business model can generally be divided into CRO (Contract Research Outsourcing) and CMO (Contract Manufacturing Outsourcing). In the past, pharmaceutical intermediates primarily adopted the CMO outsourcing model. Under the CMO model, pharmaceutical companies outsource the production process to partners. Therefore, the business chain typically starts with specialized pharmaceutical raw materials. Companies in the industry need to purchase basic chemical raw materials and process them into specialized pharmaceutical raw materials, which are then further processed to gradually form starting materials for APIs, cGMP intermediates, active pharmaceutical ingredients (APIs), and finished formulations.

However, with the continuous expiration of patents held by leading multinational pharmaceutical companies, the ongoing development of new drug innovation, the increasing difficulty in discovering and screening new compounds, and the rising challenges in subsequent approval processes, R&D costs are growing, and there is an urgent need to optimize the timeline for new drug development to ensure that the patent period yields genuine benefits. As a result, while maintaining high levels of R&D investment, large pharmaceutical companies are increasingly seeking to improve R&D efficiency and optimize cost control, leading them to outsource more R&D and production work to CDMO enterprises and integrated new drug development service companies.

This provides CDMO enterprises with increasingly numerous and clearer opportunities to deeply participate in the product supply chain from early development and clinical research to commercial production. The CDMO model (Contract Development and Manufacturing Organization) has emerged accordingly. CDMOs require custom manufacturing enterprises to engage in the client’s R&D process, providing process improvements or optimizations to achieve high-quality, large-scale production and reduce production costs. Compared to the CMO model, the CDMO model offers higher profit margins.

Jiangsu Aikon provides high-quality products, convenient and fast. Quality assured, after-sales service guaranteed.

One-stop procurement service, saving time and effort. Affordable prices, reliable quality.